Multiple Sclerosis and Related Autoimmune Neuroinflammatory Disorders
This community focuses on the clinical management, diagnostic imaging, and immunological mechanisms of multiple sclerosis and closely related conditions such as neuromyelitis optica spectrum disorder and myelin-oligodendrocyte glycoprotein antibody-associated disease. The work addresses how to identify disease activity, monitor progression, and apply targeted therapies to patients with these central nervous system disorders.
The research is dominated by studies on relapsing-remitting and progressive multiple sclerosis, with significant attention to neuromyelitis optica spectrum disorder and autoimmune encephalitis. Recurring methods include magnetic resonance imaging for lesion detection, cerebrospinal fluid analysis, and the use of neurofilament light chain as a biomarker. Therapeutic strategies frequently discussed involve disease-modifying treatments, monoclonal antibodies, and emerging cell-based therapies such as CAR-T cells. The literature also covers the pathophysiology of myelin damage, oligodendrocyte function, and the role of Epstein-Barr virus in disease onset, alongside the clinical differentiation of these conditions from other neurodegenerative or infectious processes.
The largest share of the community's output is found in gadolinium research, accounting for 3.0% of all gadolinium research, and 1,867 papers here. Phosphorus research also features prominently, with 736 papers representing 0.2% of that element's research.
The community comprises 13,516 papers, published most frequently in Neurology, Multiple Sclerosis Journal, and Multiple Sclerosis and Related Disorders.
Recent work continues to focus on the molecular pathogenesis of multiple sclerosis, the link between Epstein-Barr virus and specific T-cell responses, and the application of CAR-T therapy in progressive cases. Studies also examine the use of neurofilament biomarkers for monitoring neuroinflammation and the efficacy of monoclonal antibodies in primary progressive multiple sclerosis, while addressing challenges in remyelination and the management of neuromyelitis optica spectrum disorder attacks.